RESUMO
OBJECTIVES: The aim is to review current literature related to the diagnosis, management, and follow-up of suspected and confirmed Covid-19 cases. KEY FINDINGS: Medical Imaging plays an important auxiliary role in the diagnosis of Covid-19 patients, mainly those most seriously affected. Practice differs widely among different countries, mainly due to the variability of access to resources (viral testing and imaging equipment, specialised staff, protective equipment). It has been now well-documented that chest radiographs should be the first-line imaging tool and chest CT should only be reserved for critically ill patients, or when chest radiograph and clinical presentation may be inconclusive. CONCLUSION: As radiographers work on the frontline, they should be aware of the potential risks associated with Covid-19 and engage in optimal strategies to reduce these. Their role in vetting, conducting and often reporting the imaging examinations is vital, as well as their contribution in patient safety and care. Medical Imaging should be limited to critically ill patients, and where it may have an impact on the patient management plan. IMPLICATIONS FOR PRACTICE: At the time of publication, this review offers the most up-to-date recommendations for clinical practitioners in radiology departments, including radiographers. Radiography practice has to significantly adjust to these new requirements to support optimal and safe imaging practices for the diagnosis of Covid-19. The adoption of low dose CT, rigorous infection control protocols and optimal use of personal protective equipment may reduce the potential risks of radiation exposure and infection, respectively, within Radiology departments.
Assuntos
Infecções por Coronavirus/diagnóstico por imagem , Infecções por Coronavirus/epidemiologia , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Pneumonia Viral/diagnóstico por imagem , Pneumonia Viral/epidemiologia , Radiologistas/organização & administração , Serviço Hospitalar de Radiologia/organização & administração , Síndrome Respiratória Aguda Grave/diagnóstico por imagem , COVID-19 , Infecções por Coronavirus/diagnóstico , Feminino , Humanos , Controle de Infecções/métodos , Masculino , Saúde Ocupacional , Pandemias , Segurança do Paciente , Assistência Centrada no Paciente/organização & administração , Pneumonia Viral/diagnóstico , Radiografia Torácica/métodos , Radiografia Torácica/estatística & dados numéricos , Gestão da Segurança , Sensibilidade e Especificidade , Síndrome Respiratória Aguda Grave/epidemiologia , Tomografia Computadorizada por Raios X/métodos , Tomografia Computadorizada por Raios X/estatística & dados numéricos , Ultrassonografia Doppler/métodos , Ultrassonografia Doppler/estatística & dados numéricosRESUMO
Eight patients with idiopathic myelofibrosis (IMF) were treated with escalating doses (0.5 microgram/day to 4.0 micrograms/day) of 1 alpha(OH)D3 for periods up to 6 months. The treatment did not improve the disease parameters in any of the patients under study. No patient demonstrated a decrease in bone marrow fibrosis as determined by serial procollagen (PC III) serum level analysis. Although 1 alpha(OH)D3 was well tolerated at the administered doses, the therapeutic value of this treatment for IMF requires further evaluation.